VivoSeq
Cardiovascular

Hypertension (HTN)

2

Pipeline Programs↗

7

Active Trials↗

3

Companies Involved↗

Hypertension (HTN) is an early-stage landscape with 2 programs across 3 companies. The most active players are Novartis, Boehringer Ingelheim, Vivek Bhalla.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

27/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

PreclinicalV

Vivek Bhalla

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical1

Empagliflozin

Boehringer Ingelheim

Phase 1
No programs
Phase 21

QCZ484

Novartis

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

9

clinical trials

Not yet recruiting6 · 67%
Completed2 · 22%
Recruiting1 · 11%

Clinical Trials

Trial Activity

9 trials

A Multicenter Open-label Extension Study to Evaluate Long-term Safety and Efficacy of QCZ484 in Hypertensive Patients.
Recruiting·Novartis logoNovartis·Phase 2·NCT07543120·323 enrolled
Feasibility and Efficacy Pilot of a Team-Based Shared Decision-Making Program in Cardiovascular-Kidney-Metabolic Health, Medication Adherence, and Cardiovascular Health
Not yet recruiting·JJohns Hopkins University·Phase 1·NCT07662616·94 enrolled
Navigating Hypertension and Food Insecurity: A Produce Prescription Program to Improve Health Outcomes for Native Hawaiian and Pacific Islander Communities
Not yet recruiting·UUniversity of Hawaii·Preclinical·NCT07544836·250 enrolled
Multilevel Mobile Health Program to Improve Hypertension Among Midlife Women After Hypertensive Disorder of Pregnancy
Not yet recruiting·UUniversity of Pittsburgh·Preclinical·NCT07599579·50 enrolled
Project HOPE (Hypertension Outreach Through Partnership and Engagement)
Not yet recruiting·JJohns Hopkins University·N/A·NCT07681726·150 enrolled
Finerenone and Empagliflozin Combination in Obesity With Hypertension: A 12-Week Prospective, Parallel-design, Double-blind, Randomized, Placebo-controlled Trial
Not yet recruiting·Heart Health Research Center·Preclinical·NCT07678151·260 enrolled
Prospective Early Patient Experience Initiative (IMPACT-HTN)
Not yet recruiting·—·N/A·NCT07579260·100 enrolled
University of Georgia Mind Your Heart Pilot Study
Completed·UUniversity of Georgia·Preclinical·NCT07670910·37 enrolled
Utilidad Del Protocolo VExUS en el Ajuste de Peso Ideal de Los Pacientes en hemodiálisis
Completed·FFundación Senefro·Preclinical·NCT07659197·72 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)